Investigation of Pharmacokinetics, Safety and Tolerability of a Single Subcutaneous Dose of NNC0194-0499 in Participants With Various Degrees of Renal Impairment and Normal Renal Function
Latest Information Update: 08 Dec 2023
At a glance
- Drugs NNC0194 0499 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
Most Recent Events
- 05 Dec 2023 Status changed from active, no longer recruiting to completed.
- 04 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 29 Mar 2023 Status changed from not yet recruiting to recruiting.